




RealRate

PHARMACEUTICAL 2022

Vincerx Pharma Inc
Rank 151 of 471



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Vincerx Pharma Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Vincerx Pharma Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 54% points. The greatest weakness of Vincerx Pharma Inc is the variable Other Revenues, reducing the Economic Capital Ratio by 14% points.

The company's Economic Capital Ratio, given in the ranking table, is 346%, being 71% points above the market average of 275%.

Input Variable	Value in 1000 USD
Assets, Current	111,841
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	13,919
Liabilities, Non-Current	3,436
Other Assets	5,602
Other Compr. Net Income	-21
Other Expenses	0
Other Liabilities	0
Other Net Income	23,350
Other Revenues	0
Property and Equipment	233
Research and Development	40,081
Selling, General and Administrative Expense	22,575

Output Variable	Value in 1000 USD
Assets	117,676
Liabilities	17,355
Expenses	62,656
Revenues	0
Stockholders Equity	100,321
Net Income	-39,306
Comprehensive Net Income	-39,316
BaseVar	110,529
ECR before LimitedLiability	266%
Economic Capital Ratio	346%